Managers / Q4 2019 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $266M in U.S.-listed holdings across 12 positions for Q4 2019.
Its largest position, QURE, represents 10.7% of the portfolio.
Compared with Q3 2019, the fund opened 3 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 44.7% · $119M
- Common Stock · 37.0% · $99M
- Other · 12.7% · $34M
- ADR · 5.7% · $15M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| DICERNA PHARMACEUTICALS INC | NEW | +614.4K | 614.4K | +$14M | $14M |
| RGNXREGENXBIO INC | NEW | +268.8K | 268.8K | +$11M | $11M |
| MORPHOSYS AG | NEW | +6.1K | 6.1K | +$217,000 | $217,000 |
| XBISPDR SERIES TRUST | ADDED | +750.0K | 1.25M | +$81M | $119M |
| PROQR THRAPEUTICS N V | ADDED | +1.09M | 1.92M | +$14M | $19M |
| BCYCBICYCLE THERAPEUTICS PLC | SOLD OUT | −767.0K | 0 | −$9M | $0 |
| PIERIS PHARMACEUTICALS INC | ADDED | +2.01M | 4.97M | +$8M | $18M |
| QUREUNIQURE NV | TRIMMED | −394.3K | 396.9K | −$3M | $28M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | QUREUNIQURE NVhistory → | SHS | 10.68% | $28M | 396.9K |
| 2 | PROQR THRAPEUTICS N V | SHS EURO | 7.16% | $19M | 1.92M |
| 3 | PIERIS PHARMACEUTICALS INC | COM | 6.67% | $18M | 4.97M |
| 4 | XENEXENON PHARMACEUTICALS INChistory → | COM | 5.75% | $15M | 1.17M |
| 5 | GALAPAGOS NV | SPON ADR | 5.59% | $15M | 72.0K |
| 6 | MERUS N V | COM | 5.49% | $15M | 1.04M |
| 7 | DICERNA PHARMACEUTICALS INC | COM | 5.08% | $14M | 614.4K |
| 8 | SPROSPERO THERAPEUTICS INChistory → | COM | 4.17% | $11M | 1.15M |
| 9 | RGNXREGENXBIO INChistory → | COM | 4.14% | $11M | 268.8K |
| 10 | FATEFATE THERAPEUTICS INC | COM | 0.53% | $1M | 72.3K |
| 11 | MORPHOSYS AG | SPONSORED ADS | 0.08% | $217,000 | 6.1K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.